The botanical explorer's legacy: a promising bioprospecting tool.

Abstract:

:Records about the traditional uses of medicinal plants can be considered useful in bioprospecting (i.e., the search for new active agents or lead structures in nature). Several sources like Egyptian papyri, early modern herbals and pharmacopoeias have been studied in this respect. It is proposed to use recordings of botanically interested explorers of the 19th and early 20th centuries as well. Some of them give detailed information about traditionally used medicinal plants and analysis shows that a considerable number of these have never been scientifically investigated. Existing studies, however, are confirming the traditional uses described to a great extent. Thus, the explorer's writings should not be neglected while looking for starting points for plant screening; success seems more likely than with screening at random.

journal_name

Drug Discov Today

journal_title

Drug discovery today

authors

Helmstädter A

doi

10.1016/j.drudis.2016.11.011

subject

Has Abstract

pub_date

2017-05-01 00:00:00

pages

757-760

issue

5

eissn

1359-6446

issn

1878-5832

pii

S1359-6446(16)30429-9

journal_volume

22

pub_type

历史文章,杂志文章
  • Model fluids representing aqueous in-vitro diagnostic reagents for the development of dispensing systems.

    abstract::Analyzers for in-vitro diagnostic (IVD) testing facilitate the determination of medical information from biological samples. To reach a high quality, the detection reagents have to be dispensed with a high degree of precision and accuracy. A technology change from conventional pipetting systems to contact-free dispens...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2013.06.011

    authors: Losleben N,Spinke J,Adler S,Oranth N,Zengerle R

    更新日期:2013-11-01 00:00:00

  • Nanovehicles for co-delivery of anticancer agents.

    abstract::Effective cancer treatment remains a significant challenge in human healthcare. Although many different types of cancer therapy have been tested, scientists have now concluded that combinations of drugs, or drugs plus gene therapy, can target multiple pathways to fight cancer. Nanovehicles can increase drug uptake ins...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2020.06.027

    authors: Zeinali M,Abbaspour-Ravasjani S,Ghorbani M,Babazadeh A,Soltanfam T,Santos AC,Hamishehkar H,Hamblin MR

    更新日期:2020-08-01 00:00:00

  • Magnetic nanoformulations for prostate cancer.

    abstract::Magnetic nanoparticles (MNPs) play a vital role for improved imaging applications. Recently, a number of studies demonstrate MNPs can be applied for targeted delivery, sustained release of therapeutics, and hyperthermia. Based on stable particle size and shape, biocompatibility, and inherent contrast enhancement chara...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.04.018

    authors: Chowdhury P,Roberts AM,Khan S,Hafeez BB,Chauhan SC,Jaggi M,Yallapu MM

    更新日期:2017-08-01 00:00:00

  • Minimizing the risk of chemically reactive metabolite formation of new drug candidates: implications for preclinical drug design.

    abstract::Many pharmaceutical companies aim to reduce reactive metabolite formation by chemical modification at early stages of drug discovery. A practice often applied is the detection of stable trapping products of electrophilic intermediates with nucleophilic trapping reagents to guide rational structure-based drug design. T...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2016.11.018

    authors: Brink A,Pähler A,Funk C,Schuler F,Schadt S

    更新日期:2017-05-01 00:00:00

  • Where is the hope for drug discovery? Let history tell the future.

    abstract::For drug discovery, historical experience is always of significance. Through examining the history of traditional medicines, we find that these medicines have more implications for drug discovery than just providing new chemical entities. The history of traditional medicines indicates that they depended more on the co...

    journal_title:Drug discovery today

    pub_type: 历史文章,杂志文章

    doi:10.1016/j.drudis.2008.07.002

    authors: Kong DX,Li XJ,Zhang HY

    更新日期:2009-02-01 00:00:00

  • Molecule-pharmacophore superpositioning and pattern matching in computational drug design.

    abstract::Three-dimensional (3D) pharmacophore modeling is a technique for describing the interaction of a small molecule ligand with a macromolecular target. Since chemical features in a pharmacophore model are well known and highly transparent for medicinal chemists, these models are intuitively understandable and have been i...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2007.09.007

    authors: Wolber G,Seidel T,Bendix F,Langer T

    更新日期:2008-01-01 00:00:00

  • Pharmaceutical patents: reconciling the human right to health with the incentive to invent.

    abstract::In developed countries that protect core aspects of the fundamental human right to the highest attainable standard of health, how does that right intersect with intellectual property rights? Here, the human rights implication of providing access to all cancer drugs recommended by experts in a developed country is cons...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2020.04.009

    authors: Khachigian LM

    更新日期:2020-07-01 00:00:00

  • Case study: technology initiative led to advanced lead optimization screening processes at Bristol-Myers Squibb, 2004-2009.

    abstract::In this paper, we review the key solutions that enabled evolution of the lead optimization screening support process at Bristol-Myers Squibb (BMS) between 2004 and 2009. During this time, technology infrastructure investment and scientific expertise integration laid the foundations to build and tailor lead optimizatio...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2012.02.012

    authors: Zhang L,Cvijic ME,Lippy J,Myslik J,Brenner SL,Binnie A,Houston JG

    更新日期:2012-07-01 00:00:00

  • The design, structures and therapeutic potential of protein epitope mimetics.

    abstract::Using a biologically relevant peptide or protein structure as a starting point for lead identification represents one of the most powerful approaches in modern drug discovery. Here, we focus on the protein epitope mimetic (PEM) approach, where folded 3D structures of peptides and proteins are taken as starting points ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2008.07.008

    authors: Robinson JA,Demarco S,Gombert F,Moehle K,Obrecht D

    更新日期:2008-11-01 00:00:00

  • Monitor: molecules and profiles.

    abstract::Monitor provides an insight into the latest developments in drug discovery through brief synopses of recent presentations and publications together with expert commentaries on the latest technologies. There are two sections: Molecules summarizes the chemistry and the pharmacological significance and biological relevan...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(00)01551-8

    authors: Lloyd AW

    更新日期:2000-09-01 00:00:00

  • In silico SNP analysis and bioinformatics tools: a review of the state of the art to aid drug discovery.

    abstract::SNPs can alter protein function and phenotype, leading to altered pharmacogenomic drug profiles. The exponential number of SNPs makes it impossible to perform wet laboratory experiments to determine the biological significance of each one. However, bioinformatics tools can be used to screen for potentially deleterious...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2011.07.005

    authors: Mah JT,Low ES,Lee E

    更新日期:2011-09-01 00:00:00

  • Pragmatic randomized trials in drug development pose new ethical questions: a systematic review.

    abstract::Implementation of pragmatic design elements in drug development could bridge the evidence gap that currently exists between the knowledge we have regarding the efficacy of a drug versus its true, comparative effectiveness in real life. We performed a review of the literature to identify the ethical challenges thus far...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2015.03.005

    authors: Kalkman S,van Thiel GJ,Grobbee DE,van Delden JJ

    更新日期:2015-07-01 00:00:00

  • Treat the brain and treat the periphery: toward a holistic approach to major depressive disorder.

    abstract::The limited medication for major depressive disorder (MDD) against an ever-rising disease burden presents an urgent need for therapeutic innovations. During recent years, studies looking at the systems regulation of mental health and disease have shown a remarkably powerful control of MDD by systemic signals. Meanwhil...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2015.03.015

    authors: Zheng X,Zhang X,Wang G,Hao H

    更新日期:2015-05-01 00:00:00

  • Can BDDCS illuminate targets in drug design?

    abstract::The fact that pharmacokinetic (PK) properties of drugs influence their interaction with protein targets is a principle known for decades. The same cannot be said for the opposite, namely that targets influence the PK properties of drugs. Evidence confirming this possibility is introduced here for the first time, as we...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.09.021

    authors: Bocci G,Benet LZ,Oprea TI

    更新日期:2019-12-01 00:00:00

  • Monoclonal antibodies for chronic refractory asthma and pipeline developments.

    abstract::Patients with severe asthma suffer persistent symptoms and/or frequent exacerbations despite high-intensity treatment. Their severe unrelenting symptoms have a huge impact on healthcare resources owing to frequent hospital admissions and requirement for intensive treatments. Consequently, there is an undeniable need f...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2012.01.012

    authors: Polosa R,Casale T

    更新日期:2012-06-01 00:00:00

  • Atomic force microscopy and drug discovery.

    abstract::Atomic force microscopy is being used ever more widely in biological imaging, because of its unique ability to provide structural information at the single molecule level and under near-physiological conditions. Detailed topographic images of potential drug targets, such as proteins and DNA, have been produced, and th...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(03)02905-2

    authors: Edwardson JM,Henderson RM

    更新日期:2004-01-15 00:00:00

  • Immunity and Alzheimer's disease: immunological perspectives on the development of novel therapies.

    abstract::Alzheimer's disease (AD) is the most common neurodegenerative disorder among older people. However, no cure or disease-modifying treatments are currently available, and the molecular and cellular mechanisms responsible for the etiology of AD remain under debate. Recent studies suggest that the immune system has a cruc...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2013.07.020

    authors: Liu YH,Zeng F,Wang YR,Zhou HD,Giunta B,Tan J,Wang YJ

    更新日期:2013-12-01 00:00:00

  • Fsp3: A new parameter for drug-likeness.

    abstract::The drug-likeness of a compound is a key factor during the initial phases of drug discovery. It can be defined as the similarity between compounds and drugs. Here, we collate research related to the fraction of sp3 carbon atoms (Fsp3), including related high-throughput screening (HTS) cases, structural modifications b...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2020.07.017

    authors: Wei W,Cherukupalli S,Jing L,Liu X,Zhan P

    更新日期:2020-07-24 00:00:00

  • Psoriasis: pathological mechanisms, current pharmacological therapies, and emerging drug delivery systems.

    abstract::Psoriasis is a chronic autoimmune skin disorder triggered by either genetic factors, environmental factors, life style, or a combination thereof. Clinical investigations have identified pathogenesis, such as T cell and cytokine-mediated, genetic disposition, antimicrobial peptides, lipocalin-2, galectin-3, vaspin, fra...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2020.09.023

    authors: Rapalli VK,Waghule T,Gorantla S,Dubey SK,Saha RN,Singhvi G

    更新日期:2020-12-01 00:00:00

  • Essential oils: from prevention to treatment of skin cancer.

    abstract::The increasing incidence of cutaneous malignancies signifies the need for multiple treatment options. Several available reviews have emphasized the potential role of various botanical extracts and naturally occurring compounds as anti-skin-cancer agents. Few studies relate to the role of chemoprevention and therapeuti...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2018.11.020

    authors: Pavithra PS,Mehta A,Verma RS

    更新日期:2019-02-01 00:00:00

  • Novel procedure for rapid pharmacokinetic screening of discovery compounds in rats.

    abstract::In therapeutic areas aimed at developing an orally administered drug, the pharmacokinetic profile of a drug candidate after oral administration in vivo is pivotal in evaluating its success. This can be done by monitoring the plasma concentration versus time after dosing and calculating the area under the curve (AUC). ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(98)01299-9

    authors: Cox KA,Dunn-Meynell K,Korfmacher WA,Broske L,Nomeir AA,Lin CC,Cayen MN,Barr WH

    更新日期:1999-05-01 00:00:00

  • Nitric oxide: a drug target for glaucoma revisited.

    abstract::A reduction in intraocular pressure (IOP) is the only recognized therapy for glaucoma. Hence, drugs exhibiting ocular hypotensive effects are important targets for antiglaucomatous drug development. IOP is determined by the equilibrium of aqueous humor production and outflow through either the trabecular meshwork or t...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.05.033

    authors: Garhöfer G,Schmetterer L

    更新日期:2019-08-01 00:00:00

  • Importance of target-mediated drug disposition for small molecules.

    abstract::Target concentration is typically not considered in drug discovery. However, if targets are expressed at relatively high concentrations and compounds have high affinity, such that most of the drug is bound to its target, in vitro screens can give unreliable information on compound affinity. In vivo, a similar situatio...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2018.06.010

    authors: Smith DA,van Waterschoot RAB,Parrott NJ,Olivares-Morales A,Lavé T,Rowland M

    更新日期:2018-12-01 00:00:00

  • Compound high-quality criteria: a new vision to guide the development of drugs, current situation.

    abstract::For several decades, the pharmaceutical industry has suffered due to major issues such as reductions of the number of FDA approved drugs and biologics. Several analyses have been highlighted that the 'druglikeness' is one of the strategies to improve succeed rates of screening such as, for instance, high-throughput sc...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.01.005

    authors: Mignani S,Huber S,Tomás H,Rodrigues J,Majoral JP

    更新日期:2016-04-01 00:00:00

  • Clinical implications of leukocyte infiltration at the choroid plexus in (neuro)inflammatory disorders.

    abstract::The choroid plexus (CP) is a highly vascularized organ located in the brain ventricles and contains a single epithelial cell layer forming the blood-cerebrospinal fluid barrier (BCSFB). This barrier is crucial for immune surveillance in health and is an underestimated gate for entry of immune cells during numerous inf...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2015.05.003

    authors: Demeestere D,Libert C,Vandenbroucke RE

    更新日期:2015-08-01 00:00:00

  • Targeting fatty acid metabolism in heart failure: is it a suitable therapeutic approach?

    abstract::The energy substrate preference of the human heart is well regulated and is modified upon aging, in that the fetal heart uses glucose, whereas the adult heart utilizes fatty acids. Various human and animal studies suggest a shift in myocardial substrate utilization and decreased rate of myocardial fatty acid uptake an...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.02.010

    authors: Arumugam S,Sreedhar R,Thandavarayan RA,Karuppagounder V,Watanabe K

    更新日期:2016-06-01 00:00:00

  • Indacaterol/glycopyrronium: a dual bronchodilator for COPD.

    abstract::Indacaterol/glycopyrronium (IND/GLY) 110/50mcg was the first once-daily, long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combination (FDC) approved in Europe for the treatment of chronic obstructive pulmonary disease (COPD). Development of IND/GLY was driven by the need to improve the...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.10.015

    authors: Banerji D,Fogel R,Patalano F

    更新日期:2018-01-01 00:00:00

  • Top 100 bestselling drugs represent an arena struggling for new FDA approvals: drug age as an efficiency indicator.

    abstract::We analyzed a list of the top 100 bestselling drugs as a struggling market for new FDA approvals. Using the time from drug approval by the FDA as a measure of drug age, our analysis showed that the top 100 bestselling drugs are getting older. This reflects the stalled launch of new drugs into the market during recent ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2015.06.015

    authors: Polanski J,Bogocz J,Tkocz A

    更新日期:2015-11-01 00:00:00

  • Enabled clinical use of an HIV-1 attachment inhibitor through drug delivery.

    abstract::The clinical advancement of HIV-1 attachment inhibitors was hindered initially by poor bioavailability. Attempts to identify improved candidates revealed that solubility and dissolution-rate-limited absorption are barriers to achieving adequate antiviral plasma levels. This was mitigated by forming nanosized drugs or ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2014.03.025

    authors: Timmins P,Brown J,Meanwell NA,Hanna GJ,Zhu L,Kadow JF

    更新日期:2014-09-01 00:00:00

  • Pancreatic lipase inhibitors from natural sources: unexplored potential.

    abstract::The prevalence of obesity is increasing at an alarming rate, but, unfortunately, only a few medications are currently on the market. Obesity is primarily regarded as a disorder of lipid metabolism and the enzymes involved in this process could be selectively targeted to develop antiobesity drugs. Recently, newer appro...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2007.07.024

    authors: Birari RB,Bhutani KK

    更新日期:2007-10-01 00:00:00